Phase I/II Study of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and tolerability of BNT141 in combination with gemcitabine and nab-paclitaxel in patients with CLDN18.2 positive tumors, including pancreatic cancer tumors.
General Information
NCT#: NCT04683939
Study ID: BNT141-01
Trial Phase: Phase I/II
Trial Sponsor: BioNTech SE
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, BNT141